Table I.
Participant characteristics for the ex vivo study
| Participant demographic characteristics | Atopic, without asthma | Asthma |
|---|---|---|
| Sex (n) | ||
| Females | 1 | 2 |
| Males | 3 | 2 |
| Race (n) | ||
| White | 2 | 2 |
| Black | 0 | 0 |
| Asian | 0 | 0 |
| Hispanic | 2 | 2 |
| Mean age, y, ± SD | 31 ± 13 | 39 ± 14 |
| Mean body mass index, kg/m2, ± SD | 25 ± 3 | 31 ± 7 |
| Age of onset (n)∗ | ||
| >12 y | N/A | 1 |
| <12 y | N/A | 2 |
| Mean duration of asthma, y, ± SD | N/A | 33 ± 15 |
| Mean Asthma Control Questionnaire score | N/A | 1.22 ± 0.76 |
| Exacerbations per year (n) | N/A | 0 |
| Feno concentration (ppb) | 41 ± 30 | 30 ± 8 |
| Atopy (% positive) | 100 | 100 |
| Mean peripheral eosinophil level, %, ± SD | 0.75 ± 0.83 | 4 ± 3 |
| Mean peripheral eosinophil level, abs (× 109/mm3), ± SD | 0.05 ± 0.05 | 0.18 ± 0.11 |
| Mean peripheral neutrophil level,%, ± SD | 57 ± 11 | 53 ± 8 |
| Mean peripheral neutrophil level, abs (× 109/mm3), ± SD | 4 ± 2 | 4 ± 2 |
| Mean FVC, %, ± SD | 105 ± 5 | 95 ± 3 |
| Mean FEV1, %, ± SD | 97 ± 10 | 90 ± 7 |
| Mean FEV1/FVC ratio, %, ± SD | 76 ± 7 | 77 ± 3 |
| PC20 level (mg/mL) | N/A | 5 ± 1 |
| Medication (n) | ||
| Short acting β-agonist | N/A | 4 |
| Leukotriene modifier | N/A | 1 |
| ICS | N/A | 0 |
| Antihistamine | N/A | 2 |
| Combination therapy (ICS/LABA) | N/A | 1 |
| Short-acting anticholinergic | N/A | 0 |
| Intranasal corticosteroid | 0 | 0 |
abs, Absolute; Feno, fractional exhaled nitric oxide; ICS, inhaled corticosteroid; LABA, long-acting β-agonist; N/A, not available; PC20, provocative concentration of methacholine that resulted in a 20% decrease in the FEV1.
∗
Age of onset is not available for 1 participant.